A RESOLUTION recognizing September 21 to 28, 2025, as Frontotemporal Degeneration Awareness Week.
HR82 is a simple House resolution recognizing September 21 through September 28, 2025, as Frontotemporal Degeneration Awareness Week in Kentucky. The resolution describes frontotemporal degeneration (FTD) as an incurable, terminal neurodegenerative disease that affects the frontal and temporal lobes and can impair speech, personality, behavior, movement, swallowing, and other functions. It emphasizes that FTD often affects people in midlife, is frequently misdiagnosed, and can take years to diagnose accurately.
The resolution also highlights the broader burden of FTD, including its impact on families, the workforce, and the healthcare system, and notes the role of advocacy organizations such as the Association for Frontotemporal Degeneration in promoting awareness, research, and support. It frames the awareness week as an opportunity for Kentuckians to learn more about the disease, support affected individuals, and encourage research toward better treatments and a cure.
HR82 does not amend or create any statutes, impose regulatory requirements, or appropriate funds. Its legal effect is limited to a formal legislative recognition of an awareness week and a directive to transmit the resolution to the named representative. The practical impact is symbolic and educational, aimed at increasing public awareness of FTD and encouraging support for research, diagnosis, and caregiver assistance.
The bill appears to have a strongly supportive and noncontroversial tone. The text is framed around compassion, awareness, and the need for greater education and research, and there is no recorded committee debate or vote history indicating opposition. Because it is a commemorative resolution, the general sentiment is best characterized as unanimous or near-unanimous support for recognizing the disease and those affected by it.
No notable points of contention are reflected in the available record. The resolution is purely declaratory and does not involve policy tradeoffs, spending, or changes to benefits or eligibility. Any discussion would likely center on the importance of awareness, diagnosis, and research funding for FTD, but no opposing viewpoints, amendments, or procedural disputes are shown in the provided materials.